ReviewHeliyon2024
Efficacy and safety of Yishen Huashi granules combined with conventional therapy in the treatment of diabetic kidney disease: A systematic review and meta-analysis.
Review in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of Jinlida granules as an adjuvant treatment for diabetic nephropathy: a systematic review and meta-analysis.Frontiers in endocrinology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ethnopharmacological relevance: Diabetic kidney disease(DKD) is a complication of diabetes. If not treated in time, it will lead to severe glomerular damage, causing irreversible damage, and ultimately may lead to uremia and even death. Yishen Huashi Granule (YSHS) is a Chinese patent medicine for treating DKD by invigorating the spleen and removing dampness, which has shown a good curative effect. Aim of the study: This study systematically evaluated the clinical efficacy and blood biochemical improvement of YSHS combined with conventional therapy (CT) in treating DKD. Materials and methods: By August 2024, four English databases (PubMed, Web of Science, the Cochrane Library, and Embase) and four Chinese databases (China National Knowledge Infrastructure (CNKI), Wanfang Database (WF), China Biological Medicine Database (CBM), and China Science and Technology Journal Database (VIP)) were searched to screen literature, extract information, and evaluate quality according to inclusion and exclusion criteria. The language of these literature is limited to Chinese and English, but not limited to published sources. Meta-analysis and bias analysis were performed using Steata 16 software and Review Manager 5.3 software. The bias risk tool in the Cochrane Handbook was used to assess the quality of the literature. At 95 % confidence interval (CI), relative risk (RR) and Cohen's d were used for the categorical and continuous variables, respectively. To evaluate heterogeneity, the Q test and I Results: A total of 28 randomized controlled trials (RCTs) comprising 2416 patients were included in this study. There were 1200 patients in the control group and 1216 in the treatment group. Compared with CT, combined YSHS therapy is more effective at improving clinical efficiency rate [RR(95 % confidence interval (CI)) = 1.26(1.21, 1.32), I Conclusion: The meta-analysis revealed that YSHS combined with CT therapy is superior to CT in improving clinical outcomes, renal function, glucose metabolism, lipid metabolism, and oxidative stress. Yishen Huashi granules is more effective and safer for Diabetic kidney disease treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.